Within the context of streptococcal antitumor therapy, it is plausible that SAgs exert their effects by priming CD8+ T lymphocytes against HSP-derived epitopes that are overexpressed in tumor cells, either on the cell surface or as circulating soluble antigens. The gene discussed is HSP90B2P; the disease is neoplasm.